Welcome to our dedicated page for Silence Therapeutics Plc American Depository Share news (Ticker: SLN), a resource for investors and traders seeking the latest updates and insights on Silence Therapeutics Plc American Depository Share stock.
Silence Therapeutics Plc (symbol: SLN) is a pioneering biotechnology company dedicated to developing innovative therapies by leveraging the body's natural RNA interference (RNAi) mechanism. This cutting-edge technology allows the selective inhibition of any gene in the genome, effectively silencing the production of disease-causing proteins.
Silence Therapeutics utilizes proprietary delivery systems to target therapeutic RNA molecules directly to specific cells, enhancing the specificity and efficacy of the treatment. The company's proprietary RNA chemistries and delivery systems are designed to improve the stability of these molecules and ensure efficient delivery, making their technology well-suited for treating life-threatening diseases.
The company's product pipeline includes two promising therapies:
- SLN360: This therapy is designed to temporarily block the message of a specific gene associated with increased cardiovascular risk. By silencing the LPA gene, SLN360 lowers the levels of lipoprotein(a) [Lp(a)], potentially reducing the risk of heart diseases, heart attacks, and strokes.
- SLN124: Aimed at addressing anemia, SLN124 targets the TMPRSS6 gene to prevent the liver from producing a hormone that controls iron levels in the body, hepcidin. By increasing hepcidin levels, SLN124 reduces iron levels in the blood, thereby promoting the production of healthy red blood cells.
Silence Therapeutics is at the forefront of RNAi-based therapies, with ongoing projects and collaborations to advance their groundbreaking treatments. For the latest updates on the company's achievements and developments, visit www.silence-therapeutics.com.
Silence Therapeutics plc (Nasdaq: SLN) presented positive data from the SLN124 healthy volunteer study at the 2021 ASH Annual Meeting. The study showed durable reductions in serum iron and transferrin saturation, with a strong safety profile and long duration of action. SLN124 targets the TMPRSS6 gene and is in development for conditions like iron loading anemia, thalassemia, and myelodysplastic syndrome. Results indicated significant hepcidin modulation and favorable safety outcomes, propelling ongoing studies in diverse hematological diseases.
On December 1, 2021, Silence Therapeutics plc (Nasdaq: SLN) announced a significant investment from Deep Track Capital, totaling approximately $22 million in American Depositary Shares from existing shareholders. This investment is seen as a vote of confidence in Silence's promising pipeline, particularly its proprietary mRNAi GOLD™ platform. The company anticipates key data from its SLN360 program in early 2022, aiming to address cardiovascular risks associated with high lipoprotein(a). This marks Silence's first day of exclusive trading on Nasdaq and a continued expansion of its U.S. institutional shareholder base.
Silence Therapeutics, a leader in RNA interference therapeutics, has successfully transitioned its trading from AIM to the Nasdaq Global Market under the ticker symbol SLN as of November 30, 2021. This move aims to enhance investor access, particularly targeting U.S. institutional funds. The last trading day on AIM was November 29, 2021, and the company encourages shareholders to convert their Ordinary Shares into American Depositary Shares (ADSs) for Nasdaq trading. Silence continues to advance its mRNAi GOLD™ platform with ongoing collaborations and product candidates addressing significant medical needs.
Silence Therapeutics will present at the Jefferies London Healthcare Conference from November 16-18, 2021. The on-demand presentation will be available starting November 18 at 8:00am GMT / 3:00am ET via the company's website. Silence Therapeutics focuses on developing siRNA therapeutics targeting diseases with significant unmet medical needs. Their proprietary mRNAi GOLD™ platform aims to treat conditions like high lipoprotein(a) levels and iron-loading anemia. Archived webcasts will also be accessible post-conference.
Silence Therapeutics plc (AIM: SLN, Nasdaq: SLN) announced that Frazier Life Sciences has acquired approximately $20 million worth of ordinary shares, becoming a 3% shareholder. This partnership underscores Silence’s potential in RNA interference technology and enhances its financial backing as it progresses with two clinical stage programs and expands its pre-clinical pipeline using its mRNAi GOLD™ platform. The move aligns with Silence's strategy to attract institutional investors, particularly after its delisting from AIM.
Silence Therapeutics (AIM:SLN, Nasdaq:SLN) announced updates on its mRNAi GOLD™ platform during its R&D Day on October 21, 2021. Key highlights include plans to initiate a Phase 1 study for polycythemia vera (PV) using SLN124, targeting a market of 3.5 million individuals. SLN360 is on track for topline data in Q1 2022, while the company aims to deliver 2-3 INDs annually from 2023. The FDA has accepted SLN124's IND for myelodysplastic syndrome (MDS), and ongoing studies in thalassemia are expected to yield topline results in Q3 2022.
Silence Therapeutics has announced plans to cancel the admission of its ordinary shares to trading on AIM and transition the primary trading venue to Nasdaq. This AIM Delisting is set to take effect on 30 November 2021, with the last trading day on AIM being 29 November 2021. The company aims to enhance liquidity for its American Depositary Shares (ADSs) and streamline operations. A general meeting is scheduled for 1 November 2021 to seek shareholder approval. This significant change is expected to attract more US-based investors and reduce compliance costs.
Silence Therapeutics (AIM:SLN, Nasdaq: SLN) and Hansoh Pharma (3692.HK) have announced a collaboration to develop therapeutics using Silence’s mRNAi GOLD™ platform. Hansoh will make an upfront cash payment of $16 million, with Silence eligible for up to $1.3 billion in milestone payments. The partnership enables exclusive rights to two targets for Silence in regions excluding China, while Hansoh retains rights in China and global rights to a third target. Silence anticipates that this collaboration will advance its proprietary programs and provide access to the significant Chinese pharmaceutical market.
Silence Therapeutics plc (AIM: SLN, Nasdaq: SLN) will host its R&D Day on October 21, 2021, in New York City, featuring presentations on its mRNAi GOLD™ platform programs. This includes insights into lead clinical programs SLN360, targeting cardiovascular disease from high lipoprotein(a), and SLN124, aimed at treating thalassemia and myelodysplastic syndrome. The event will run from 9:00 a.m. to 11:30 a.m. EDT and will be available via a live webcast. Attendees must pre-register and provide proof of COVID-19 vaccination to enter.
Silence Therapeutics (AIM: SLN, Nasdaq: SLN) will participate in a fireside chat during the Chardan Virtual Genetic Medicines Conference on October 5 at 8:30 a.m. EDT. The event highlights the company's innovative siRNA therapeutics aimed at addressing diseases with significant unmet medical needs. A live webcast will be available on their website, and an archived replay will follow. Silence's ongoing projects include SLN360 for cardiovascular risk and SLN124 for iron-loading anemia.
FAQ
What is the current stock price of Silence Therapeutics Plc American Depository Share (SLN)?
What is the market cap of Silence Therapeutics Plc American Depository Share (SLN)?
What is Silence Therapeutics Plc?
What is RNA interference (RNAi)?
What is SLN360 therapy?
What is SLN124 therapy?
How does Silence Therapeutics target specific cells?
What diseases are Silence Therapeutics' therapies targeting?
How does SLN360 reduce cardiovascular risks?
What is the role of hepcidin in SLN124 therapy?
Where can I find more information about Silence Therapeutics' projects?
What makes Silence Therapeutics unique?
